Supplementary Figure 2 from Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical TrialSerena Di Cosimo, José Baselga, Sriram Sathyanarayanan et al.|Unknown|2023Cited by 0
Supplementary Methods, Tables 1 - 4, Figure Legends from Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical TrialSerena Di Cosimo, José Baselga, Sriram Sathyanarayanan et al.|Unknown|2023Cited by 0
Supplementary Figure 3 from Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical TrialSerena Di Cosimo, José Baselga, Sriram Sathyanarayanan et al.|Unknown|2023Cited by 0
Supplementary Figure 4 from Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical TrialSerena Di Cosimo, José Baselga, Sriram Sathyanarayanan et al.|Unknown|2023Cited by 0
Supplementary Figure 1 from Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical TrialSerena Di Cosimo, José Baselga, Sriram Sathyanarayanan et al.|Unknown|2023Cited by 0